Table 4.
Factors associated with event-free survival of IBS
| Risk factor | HR (95%CI) |
P |
|---|---|---|
| Log Rank test risk factor | ||
| Male sex | 0.57 (0.30–1.09) | 0.09 |
| Onset of BS < 7 years | 2.25 (1.17–4.33) | 0.015 |
| WBC > 6.4, × 109/L | 1.77 (0.94–3.32) | 0.077 |
| Hb < 123, g/L | 1.55 (0.83–2.92) | 0.172 |
| ESR > 24, mm/h | 2.18 (1.11–4.28) | 0.024 |
| Biologics | 0.369 (0.192–0.710) | 0.003 |
| IFX therapy# | 0.46 (0.22–0.95) | 0.035 |
| Poor compliance | 3.26 (1.73–6.13) | 0.000 |
| Multiple Cox regression risk factor | ||
| Onset of BS < 7 years | 2.43 (1.24–4.76) | 0.010 |
| ESR > 24, mm/h | 1.97 (0.99–3.91) | 0.053 |
| Poor compliance |
3.06 (1.61–5.80) |
0.001 |
#IFX therapy was administrated at 0, 2, and 6 weeks (intravenous), and then maintained with the same dosage of IFX every 8 weeks